Skip to main content
Contact Us
Subscribe
E-Edition
72°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adaptimmune Therapeutics plc - American Depositary Shares
(NQ:
ADAP
)
0.2500
+0.0530 (+26.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Adaptimmune Therapeutics plc - American Depositary Shares
< Previous
1
2
3
4
5
Next >
What Analysts Are Saying About Adaptimmune Therapeutics Stock
Today 9:01 EDT
Via
Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
March 20, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
Here are the top movers in Thursday's session.
March 20, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Top movers in Thursday's session
March 20, 2025
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst Reviews
November 27, 2024
Via
Benzinga
Earnings Scheduled For November 13, 2024
November 13, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
March 20, 2025
Via
Benzinga
Which stocks are gapping on Thursday?
March 20, 2025
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results
March 20, 2025
Via
Benzinga
Topics
Stocks
Exposures
US Equities
An Overview of Adaptimmune Therapeutics's Earnings
November 12, 2024
Via
Benzinga
The Latest Analyst Ratings For Adaptimmune Therapeutics
August 05, 2024
Via
Benzinga
Why Adaptimmune Therapeutics (ADAP) Stock Is Moving
May 31, 2024
Adaptimmune Therapeutics shares are trading higher by 15.8% during Friday's session. The company and Galapagos entered a clinical collaboration.
Via
Benzinga
Adaptimmune Therapeutics Earnings Preview
March 05, 2024
Via
Benzinga
Earnings Scheduled For March 20, 2025
March 20, 2025
Via
Benzinga
ADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 12, 2024
ADAP stock results show that Adaptimmune Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
August 12, 2024
Via
Benzinga
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
August 02, 2024
FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S.,...
Via
Benzinga
Exposures
Product Safety
3 Biotech Moonshots With Imminent Catalyst Potential
July 03, 2024
Biotech has been one of the most explosive sectors. Better, further upside is likely, thanks to some of the top biotech stocks with catalysts.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 31, 2024
Via
Benzinga
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 31, 2024
Via
Benzinga
Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
May 31, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 31, 2024
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers on Friday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
May 30, 2024
Via
Benzinga
ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 15, 2024
ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
April 19, 2024
Via
Benzinga
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 08, 2024
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
Via
Benzinga
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
March 08, 2024
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 06, 2024
ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 06, 2024
Via
Benzinga
Earnings Scheduled For March 6, 2024
March 06, 2024
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.